New study shows Alzheimer’s disease can be reversed in animal models to achieve full neurological recovery, not just prevented or slowed

A research team led by Kalyani Chaubey and Andrew Pieper reports in Cell Reports Medicine that the pharmacologic agent P7C3-A20 restored NAD+ balance and reversed pathology and cognitive deficits in two distinct mouse models of advanced Alzheimer’s disease, with accompanying normalization of plasma phosphorylated tau217. The study highlights NAD+ maintenance as a potential therapeutic node, warns against indiscriminate use of OTC NAD+ precursors, and notes commercialization plans via Cleveland-based Glengary Brain Health, setting the stage for carefully designed human clinical trials but leaving clinical efficacy and regulatory outcomes untested to date.

Analysis

Market structure: A credible, reproducible NAD+ reversal pathway would disproportionately benefit CNS-focused biotech platforms (small/mid caps) and diagnostics/CROs that run AD trials; winners gain pricing power for platform therapies and diagnostics (p‑tau217 testing). Losers include OTC NAD+ supplement pure‑plays and single‑mechanism anti‑amyloid companies that lack diversified CNS platforms; payer pushback could compress launch pricing if therapies seek broad use. Competitive dynamics: Big Pharma (capacity to fund large Phase 2/3) will likely consolidate promising NAD+ platforms via M&A, increasing valuation dispersion—expect midcaps to see 20–50% re‑rating on credible IND/Phase‑1 readouts within 12–24 months. Supply/demand: Clinical trial demand will rise, tightening CRO/CDMO capacity and lifting pricing/margins for ICLR/LH/TMO over 6–18 months.

Risk assessment: Tail risks include non‑translation to humans, unexpected oncogenic signals, IP disputes with university/licensing entity, and regulatory rejection; probability of translation within 2 years is low (~10–20%) but upside is binary/high. Time horizons: immediate PR-driven equity pops (days–weeks), partnership/IND catalysts (3–12 months), approval/commercial inflection (3–7 years). Hidden dependencies include licensing terms (Glengary/University) and biomarker assay standardization (p‑tau217 adoption); key catalysts are IND filings, Phase‑1 safety readouts, and patent grants.

Trade implications: Favor exposure to trial infrastructure and diagnostics over speculative single‑asset plays: long CROs/diagnostics, selective long midcap CNS platforms with clean IP, and caution on consumer supplement names. Use options to size asymmetric exposure to 12–24 month binary readouts (LEAP call spreads). Entry: scale in on up to 10% short‑term pop fade, add on IND/Phase‑1 positive data; exits at predefined catalysts or 25–40% stop losses. Contrarian angle: Consensus underweights licensing/IP risk and overestimates mouse→human translation; historical parallels (BACE failures) argue for conservatism—allocate small, staged positions until clinical proof.

Key Decisions for Investors

• Establish a 2–3% portfolio position long in biotech ETF XBI to capture re‑rating of small/mid CNS developers; size in over 2–6 weeks, trim 30–50% on any >25% pop and add back only after IND/Phase‑1 filings (6–12 months).
• Initiate a 1–2% long position in ICON plc (ICLR) or Labcorp (LH) to play increased AD trial demand; target 15–30% upside over 6–18 months as CRO capacity tightens; set a 20% stop loss.
• Buy a 12–18 month call spread on Biogen (BIIB) (e.g., buy 30% OTM LEAP, sell 10–15% OTM LEAP) sized to 0.5–1% portfolio to gain asymmetric upside if NAD+ platforms drive partnerships/M&A; close on partner announcement or 40% profit.
• Establish a small (0.5–1%) short position in ChromaDex (CDXC) and other pure‑play OTC NAD+ supplement names, because regulatory guidance and university warnings could reduce demand; use a tight 30% stop and monitor FDA/FTC actions within 30–90 days.
• Do not take large single‑asset long positions in any P7C3‑linked or Glengary‑licensed company until the IND is filed and first human safety data are reported (monitor for IND within 6 months and Phase‑1 readout within 12–18 months as a go/no‑go trigger).